Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 209

1.

Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer.

Latham A, Srinivasan P, Kemel Y, Shia J, Bandlamudi C, Mandelker D, Middha S, Hechtman J, Zehir A, Dubard-Gault M, Tran C, Stewart C, Sheehan M, Penson A, DeLair D, Yaeger R, Vijai J, Mukherjee S, Galle J, Dickson MA, Janjigian Y, O'Reilly EM, Segal N, Saltz LB, Reidy-Lagunes D, Varghese AM, Bajorin D, Carlo MI, Cadoo K, Walsh MF, Weiser M, Aguilar JG, Klimstra DS, Diaz LA Jr, Baselga J, Zhang L, Ladanyi M, Hyman DM, Solit DB, Robson ME, Taylor BS, Offit K, Berger MF, Stadler ZK.

J Clin Oncol. 2018 Oct 30:JCO1800283. doi: 10.1200/JCO.18.00283. [Epub ahead of print]

PMID:
30376427
2.

Assessing the Value of Next-Generation Sequencing Tests in a Dynamic Environment.

Burris HA, Saltz LB, Yu PP.

Am Soc Clin Oncol Educ Book. 2018 May 23;(38):139-146. doi: 10.1200/EDBK_200825. Review.

3.

Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas.

Liu S, Gӧnen M, Stadler ZK, Weiser MR, Hechtman JF, Vakiani E, Wang T, Vyas M, Joneja U, Al-Bayati M, Segal NH, Smith JJ, King S, Guercio S, Ntiamoah P, Markowitz AJ, Zhang L, Cercek A, Garcia-Aguilar J, Saltz LB, Diaz LA, Klimstra DS, Shia J.

Mod Pathol. 2018 Aug 30. doi: 10.1038/s41379-018-0114-7. [Epub ahead of print]

PMID:
30166615
4.

Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance).

Guercio BJ, Zhang S, Niedzwiecki D, Li Y, Babic A, Morales-Oyarvide V, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Zoltick ES, Stampfer M, Ng K, Wu K, Willett WC, Giovannucci EL, Meyerhardt JA, Fuchs CS.

PLoS One. 2018 Jul 19;13(7):e0199244. doi: 10.1371/journal.pone.0199244. eCollection 2018.

5.

Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance).

Brown JC, Zhang S, Niedzwiecki D, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Li Y, Zhang X, Ng K, Willett WC, Giovannucci EL, Fuchs CS, Meyerhardt JA.

JNCI Cancer Spectr. 2018 Feb;2(2):pky017. doi: 10.1093/jncics/pky017. Epub 2018 May 30.

6.

Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.

Lowery MA, Ptashkin R, Jordan E, Berger MF, Zehir A, Capanu M, Kemeny NE, O'Reilly EM, El-Dika I, Jarnagin WR, Harding JJ, D'Angelica MI, Cercek A, Hechtman JF, Solit DB, Schultz N, Hyman DM, Klimstra DS, Saltz LB, Abou-Alfa GK.

Clin Cancer Res. 2018 Sep 1;24(17):4154-4161. doi: 10.1158/1078-0432.CCR-18-0078. Epub 2018 May 30.

PMID:
29848569
7.

Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis: The CALGB 89803/Alliance Trial.

Van Blarigan EL, Fuchs CS, Niedzwiecki D, Zhang S, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Giovannucci EL, Ng K, Meyerhardt JA.

JAMA Oncol. 2018 Jun 1;4(6):783-790. doi: 10.1001/jamaoncol.2018.0126.

PMID:
29710284
8.

Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer.

Cercek A, Roxburgh CSD, Strombom P, Smith JJ, Temple LKF, Nash GM, Guillem JG, Paty PB, Yaeger R, Stadler ZK, Seier K, Gonen M, Segal NH, Reidy DL, Varghese A, Shia J, Vakiani E, Wu AJ, Crane CH, Gollub MJ, Garcia-Aguilar J, Saltz LB, Weiser MR.

JAMA Oncol. 2018 Jun 14;4(6):e180071. doi: 10.1001/jamaoncol.2018.0071. Epub 2018 Jun 14.

PMID:
29566109
9.

Can We Afford That CAR? Confronting the Effect of Novel Immunotherapies on Future Health Care Costs.

Green AK, Saltz LB.

J Clin Oncol. 2018 May 1;36(13):1381-1382. doi: 10.1200/JCO.2018.78.4397. Epub 2018 Mar 16. No abstract available.

PMID:
29547344
10.

Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance).

Fadelu T, Zhang S, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson AB, Atienza DM, Messino M, Kindler HL, Venook A, Ogino S, Ng K, Wu K, Willett W, Giovannucci E, Meyerhardt J, Bao Y, Fuchs CS.

J Clin Oncol. 2018 Apr 10;36(11):1112-1120. doi: 10.1200/JCO.2017.75.5413. Epub 2018 Feb 28.

PMID:
29489429
11.

Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations.

Hu ZI, Shia J, Stadler ZK, Varghese AM, Capanu M, Salo-Mullen E, Lowery MA, Diaz LA Jr, Mandelker D, Yu KH, Zervoudakis A, Kelsen DP, Iacobuzio-Donahue CA, Klimstra DS, Saltz LB, Sahin IH, O'Reilly EM.

Clin Cancer Res. 2018 Mar 15;24(6):1326-1336. doi: 10.1158/1078-0432.CCR-17-3099. Epub 2018 Jan 24.

PMID:
29367431
12.

Marine ω-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance).

Van Blarigan EL, Fuchs CS, Niedzwiecki D, Ye X, Zhang S, Song M, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Giovannucci EL, Meyerhardt JA.

Cancer Epidemiol Biomarkers Prev. 2018 Apr;27(4):438-445. doi: 10.1158/1055-9965.EPI-17-0689. Epub 2018 Jan 22.

PMID:
29358223
13.

The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia.

Overman MJ, Ferrarotto R, Raghav K, George B, Qiao W, Machado KK, Saltz LB, Mazard T, Vauthey JN, Hoff PM, Hobbs B, Loyer EM, Kopetz S.

J Natl Cancer Inst. 2018 Aug 1;110(8):888-894. doi: 10.1093/jnci/djx288.

PMID:
29346573
14.

Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma.

Harding JJ, Abu-Zeinah G, Chou JF, Owen DH, Ly M, Lowery MA, Capanu M, Do R, Kemeny NE, O'Reilly EM, Saltz LB, Abou-Alfa GK.

J Natl Compr Canc Netw. 2018 Jan;16(1):50-58. doi: 10.6004/jnccn.2017.7024.

PMID:
29295881
15.

Outcomes of ICU Admission of Patients With Progressive Metastatic Gastrointestinal Cancer.

Epstein AS, Yang A, Colbert LE, Voigt LP, Meadows J, Goldberg JI, Saltz LB.

J Intensive Care Med. 2017 Jan 1:885066617748874. doi: 10.1177/0885066617748874. [Epub ahead of print]

16.

The Impact of Primary Tumor Location on Long-Term Survival in Patients Undergoing Hepatic Resection for Metastatic Colon Cancer.

Creasy JM, Sadot E, Koerkamp BG, Chou JF, Gonen M, Kemeny NE, Saltz LB, Balachandran VP, Peter Kingham T, DeMatteo RP, Allen PJ, Jarnagin WR, D'Angelica MI.

Ann Surg Oncol. 2018 Feb;25(2):431-438. doi: 10.1245/s10434-017-6264-x. Epub 2017 Nov 27.

PMID:
29181680
17.

Author's Response.

Desai AV, Epstein AS, Colbert LE, Saltz LB.

J Pain Symptom Manage. 2018 Jan;55(1):e2-e3. doi: 10.1016/j.jpainsymman.2017.11.003. Epub 2017 Nov 13. No abstract available.

PMID:
29146195
18.

Raising the Dose and Raising the Cost: The Case of Pembrolizumab in Lung Cancer.

Bach PB, Saltz LB.

J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx125. No abstract available.

PMID:
29059436
19.

Clinical and molecular characterization of patients with cancer of unknown primary in the modern era.

Varghese AM, Arora A, Capanu M, Camacho N, Won HH, Zehir A, Gao J, Chakravarty D, Schultz N, Klimstra DS, Ladanyi M, Hyman DM, Solit DB, Berger MF, Saltz LB.

Ann Oncol. 2017 Dec 1;28(12):3015-3021. doi: 10.1093/annonc/mdx545.

20.

FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug.

Bach PB, Giralt SA, Saltz LB.

JAMA. 2017 Nov 21;318(19):1861-1862. doi: 10.1001/jama.2017.15218. No abstract available.

PMID:
28975266
21.

OncoKB: A Precision Oncology Knowledge Base.

Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, Rudolph JE, Yaeger R, Soumerai T, Nissan MH, Chang MT, Chandarlapaty S, Traina TA, Paik PK, Ho AL, Hantash FM, Grupe A, Baxi SS, Callahan MK, Snyder A, Chi P, Danila D, Gounder M, Harding JJ, Hellmann MD, Iyer G, Janjigian Y, Kaley T, Levine DA, Lowery M, Omuro A, Postow MA, Rathkopf D, Shoushtari AN, Shukla N, Voss M, Paraiso E, Zehir A, Berger MF, Taylor BS, Saltz LB, Riely GJ, Ladanyi M, Hyman DM, Baselga J, Sabbatini P, Solit DB, Schultz N.

JCO Precis Oncol. 2017 Jul;2017. doi: 10.1200/PO.17.00011. Epub 2017 May 16.

22.

Immunohistochemical null-phenotype for mismatch repair proteins in colonic carcinoma associated with concurrent MLH1 hypermethylation and MSH2 somatic mutations.

Wang T, Stadler ZK, Zhang L, Weiser MR, Basturk O, Hechtman JF, Vakiani E, Saltz LB, Klimstra DS, Shia J.

Fam Cancer. 2018 Apr;17(2):225-228. doi: 10.1007/s10689-017-0031-9.

PMID:
28819720
23.

Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, Berger MF.

Nat Med. 2017 Aug 4;23(8):1004. doi: 10.1038/nm0817-1004c. No abstract available.

PMID:
28777785
24.

Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype.

Lowery MA, Jordan EJ, Basturk O, Ptashkin RN, Zehir A, Berger MF, Leach T, Herbst B, Askan G, Maynard H, Glassman D, Covington C, Schultz N, Abou-Alfa GK, Harding JJ, Klimstra DS, Hechtman JF, Hyman DM, Allen PJ, Jarnagin WR, Balachandran VP, Varghese AM, Schattner MA, Yu KH, Saltz LB, Solit DB, Iacobuzio-Donahue CA, Leach SD, O'Reilly EM.

Clin Cancer Res. 2017 Oct 15;23(20):6094-6100. doi: 10.1158/1078-0432.CCR-17-0899. Epub 2017 Jul 28.

25.

An elderly man with remote history of metastatic melanoma now with localized pancreas cancer and new liver masses.

Vasan N, Braghiroli MI, Shoushtari AN, Do RKG, Edelweiss M, Shamseddine A, Faraj W, Mukherji D, Haydar A, Olayan A, Sabatin F, Assi R, El Dika I, Saltz LB, Abou-Alfa GK, O'Reilly EM.

J Gastrointest Oncol. 2017 Jun;8(3):596-602. doi: 10.21037/jgo.2017.01.21. No abstract available.

26.

Capecitabine With Mitomycin Reduces Acute Hematologic Toxicity and Treatment Delays in Patients Undergoing Definitive Chemoradiation Using Intensity Modulated Radiation Therapy for Anal Cancer.

Goodman KA, Julie D, Cercek A, Cambridge L, Woo KM, Zhang Z, Wu AJ, Reidy DL, Segal NH, Stadler ZK, Saltz LB.

Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(5):1087-1095. doi: 10.1016/j.ijrobp.2017.03.022. Epub 2017 Mar 22.

PMID:
28721892
27.

Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.

Abou-Alfa GK, Blanc JF, Miles S, Ganten T, Trojan J, Cebon J, Liem AK, Lipton L, Gupta C, Wu B, Bass M, Hollywood E, Ma J, Bradley M, Litten J, Saltz LB.

Oncologist. 2017 Jul;22(7):780-e65. doi: 10.1634/theoncologist.2017-0058. Epub 2017 Jun 7.

28.

How Should We Intervene on the Financial Toxicity of Cancer Care? One Shot, Four Perspectives.

Zafar SY, Newcomer LN, McCarthy J, Fuld Nasso S, Saltz LB.

Am Soc Clin Oncol Educ Book. 2017;37:35-39. doi: 10.14694/EDBK_174893.

29.

Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug.

Reidy-Lagunes DL, Lung B, Untch BR, Raj N, Hrabovsky A, Kelly C, Gerst S, Katz S, Kampel L, Chou J, Gopalan A, Saltz LB.

Oncologist. 2017 Sep;22(9):1102-1106. doi: 10.1634/theoncologist.2016-0459. Epub 2017 May 30.

30.

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, Berger MF.

Nat Med. 2017 Jun;23(6):703-713. doi: 10.1038/nm.4333. Epub 2017 May 8. Erratum in: Nat Med. 2017 Aug 4;23 (8):1004.

31.

Discharge to Subacute Rehabilitation Facilities Does Not Benefit Patients Hospitalized With Progressive Gastrointestinal Cancer.

Desai AV, Epstein AS, Colbert LE, Saltz LB.

J Pain Symptom Manage. 2017 Aug;54(2):e4-e7. doi: 10.1016/j.jpainsymman.2017.03.006. Epub 2017 Apr 22. No abstract available.

PMID:
28438586
32.

Universal screening for microsatellite instability in colorectal cancer in the clinical genomics era: new recommendations, methods, and considerations.

Hechtman JF, Middha S, Stadler ZK, Zehir A, Berger MF, Vakiani E, Weiser MR, Ladanyi M, Saltz LB, Klimstra DS, Shia J.

Fam Cancer. 2017 Oct;16(4):525-529. doi: 10.1007/s10689-017-9993-x. No abstract available.

PMID:
28405781
33.

Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance).

Fuchs MA, Yuan C, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Innocenti F, Warren RS, Bertagnolli MM, Ogino S, Giovannucci EL, Horvath E, Meyerhardt JA, Ng K.

Ann Oncol. 2017 Jun 1;28(6):1359-1367. doi: 10.1093/annonc/mdx109.

34.

Reply to G. Le Flahec et al.

Stadler ZK, Saltz LB.

J Clin Oncol. 2017 Jan 20;35(3):378. doi: 10.1200/JCO.2016.69.9413. Epub 2016 Oct 24. No abstract available.

PMID:
28095264
35.

A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803.

Niedzwiecki D, Hasson RM, Lenz HJ, Ye C, Redston M, Ogino S, Fuchs CS, Compton CC, Mayer RJ, Goldberg RM, Colacchio TA, Saltz LB, Warren RS, Bertagnolli MM.

Oncologist. 2017 Jan;22(1):107-114. doi: 10.1634/theoncologist.2016-0215. Epub 2016 Nov 7.

36.

Bevacizumab in colorectal cancer: it should have worked.

Saltz LB.

Lancet Oncol. 2016 Nov;17(11):1469-1470. doi: 10.1016/S1470-2045(16)30213-3. Epub 2016 Sep 19. No abstract available.

PMID:
27660191
37.

Value in Colorectal Cancer Treatment: Where It Is Lacking, and Why.

Saltz LB.

Cancer J. 2016 May-Jun;22(3):232-5. doi: 10.1097/PPO.0000000000000194. Review.

38.

Faster FOLFOX: Oxaliplatin Can Be Safely Infused at a Rate of 1 mg/m2/min.

Cercek A, Park V, Yaeger R, Reidy-Lagunes D, Kemeny NE, Stadler ZK, Segal NH, Varghese A, Saltz LB.

J Oncol Pract. 2016 May;12(5):e548-53. doi: 10.1200/JOP.2015.008417. Epub 2016 Apr 12.

39.

Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels.

Stadler ZK, Battaglin F, Middha S, Hechtman JF, Tran C, Cercek A, Yaeger R, Segal NH, Varghese AM, Reidy-Lagunes DL, Kemeny NE, Salo-Mullen EE, Ashraf A, Weiser MR, Garcia-Aguilar J, Robson ME, Offit K, Arcila ME, Berger MF, Shia J, Solit DB, Saltz LB.

J Clin Oncol. 2016 Jun 20;34(18):2141-7. doi: 10.1200/JCO.2015.65.1067. Epub 2016 Mar 28.

40.

A Phase II Efficacy and Safety, Open-Label, Multicenter Study of Imprime PGG Injection in Combination With Cetuximab in Patients With Stage IV KRAS-Mutant Colorectal Cancer.

Segal NH, Gada P, Senzer N, Gargano MA, Patchen ML, Saltz LB.

Clin Colorectal Cancer. 2016 Sep;15(3):222-7. doi: 10.1016/j.clcc.2016.02.013. Epub 2016 Feb 13.

41.

Multiparametric MRI in the assessment of response of rectal cancer to neoadjuvant chemoradiotherapy: A comparison of morphological, volumetric and functional MRI parameters.

Hötker AM, Tarlinton L, Mazaheri Y, Woo KM, Gönen M, Saltz LB, Goodman KA, Garcia-Aguilar J, Gollub MJ.

Eur Radiol. 2016 Dec;26(12):4303-4312. Epub 2016 Mar 5.

42.

Overspending driven by oversized single dose vials of cancer drugs.

Bach PB, Conti RM, Muller RJ, Schnorr GC, Saltz LB.

BMJ. 2016 Feb 29;352:i788. doi: 10.1136/bmj.i788. No abstract available.

PMID:
26932932
43.

Genetic Screening in All Young Patients With Colorectal Cancer?

Saltz LB.

J Clin Oncol. 2016 May 1;34(13):1560. doi: 10.1200/JCO.2015.65.9847. Epub 2016 Feb 29. No abstract available.

PMID:
26926689
44.

Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database.

Cheung WY, Renfro LA, Kerr D, de Gramont A, Saltz LB, Grothey A, Alberts SR, Andre T, Guthrie KA, Labianca R, Francini G, Seitz JF, O'Callaghan C, Twelves C, Van Cutsem E, Haller DG, Yothers G, Sargent DJ.

J Clin Oncol. 2016 Apr 10;34(11):1182-9. doi: 10.1200/JCO.2015.65.1158. Epub 2016 Feb 8.

45.

The Value of Considering Cost, and the Cost of Not Considering Value.

Saltz LB.

J Clin Oncol. 2016 Mar 1;34(7):659-60. doi: 10.1200/JCO.2015.64.7867. Epub 2015 Dec 14. No abstract available.

46.

Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database.

Renfro LA, Loupakis F, Adams RA, Seymour MT, Heinemann V, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Falcone A, Tebbutt NC, Punt CJ, Hecht JR, Bokemeyer C, Van Cutsem E, Goldberg RM, Saltz LB, de Gramont A, Sargent DJ, Lenz HJ.

J Clin Oncol. 2016 Jan 10;34(2):144-50. doi: 10.1200/JCO.2015.61.6441. Epub 2015 Oct 26.

47.

Perspectives on Cost and Value in Cancer Care.

Saltz LB.

JAMA Oncol. 2016 Jan;2(1):19-21. doi: 10.1001/jamaoncol.2015.4191. No abstract available.

PMID:
26501848
48.

Reply to A. Messori et al, R. Bordonaro et al, and G. Fasola et al.

Saltz LB.

J Clin Oncol. 2015 Nov 10;33(32):3843-4. doi: 10.1200/JCO.2015.62.9287. Epub 2015 Aug 24. No abstract available.

PMID:
26304894
49.

Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance).

Guercio BJ, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Hu FB, Ogino S, Wu K, Willett WC, Giovannucci EL, Meyerhardt JA, Fuchs CS.

J Clin Oncol. 2015 Nov 1;33(31):3598-607. doi: 10.1200/JCO.2015.61.5062. Epub 2015 Aug 17.

50.

Genomic Profiling of Cancers of Unknown Primary Site: The Next Steps.

Varghese AM, Saltz LB.

JAMA Oncol. 2015 Jul;1(4):541-2. doi: 10.1001/jamaoncol.2015.0939. No abstract available.

PMID:
26181267

Supplemental Content

Loading ...
Support Center